Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT)
Phase 3
- Conditions
- Heparin-induced Thrombocytopenia
- Interventions
- Drug: Warfarin, NOAC
- Registration Number
- NCT03147638
- Lead Sponsor
- Marshall University
- Brief Summary
Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
- Patient is unable to sign an informed consent
- Patient doesn't have a confirmed diagnosis of HIT
- Patient Does not have Pulmonary embolus
- Patient does is not on Warfarin for other indications
- Patient is a known case of hypercoagulable disorder
- Patient is not willing to come back for follow up
- Patient is critically ill or has a life expectancy of less than 3 months
- Pregnancy that is in First trimester.
- Multi-system organ failure or estimated survival of less than 30 days
- Uncontrolled hypertension defined as a blood pressure >180/110 mm Hg
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 3 months Warfarin, NOAC standard of care , treatment for 3 months 1 month Warfarin, NOAC patient treated with Anti coagulation for one month
- Primary Outcome Measures
Name Time Method All cause hospitalization Within six months after treatment side effects of Warfarin treatment Within six months after treatment All cause mortality Within six months after treatment
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Marshall University
🇺🇸Huntington, West Virginia, United States